French Retail Investors Webcast on the Topline Results from REFLECT Phase III Clinical Trial of LUMEVOQ®

KOL Webcast on the Topline Results from REFLECT Phase III Clinical Trial of LUMEVOQ®

GenSight Biologics to Host Key Opinion Leader Webcasts on the Topline Results from REFLECT Phase III Clinical Trial of LUMEVOQ®

GenSight Biologics Announces Approval of the LUMEVOQ® Cohort Temporary Authorization for Use (ATUc) in France

GenSight Biologics Reports Topline Results from REFLECT Phase III Clinical Trial, Confirming LUMEVOQ® Efficacy Including Better Efficacy with Bilateral Treatment

UMDF Mitochondrial Medicine 2021 – virtual

Clinical Operations Strategy Meeting online 2021

GenSight Biologics Announces Publication of Indirect Comparison Showing Treatment Effect of LUMEVOQ® versus Natural History in Frontiers in Neurology

GenSight Biologics to Host a Key Opinion Leader Webinar on the Nature Medicine Case Report: Visual Recovery after GS030 Optogenetic Treatment

KOL Webinar on the Nature Medicine Case Report: Visual Recovery after GS030 Optogenetic Treatment